Format

Send to

Choose Destination
Mol Pain. 2017 Jan-Dec;13:1744806917740233. doi: 10.1177/1744806917740233.

Monoclonal antibodies for chronic pain: a practical review of mechanisms and clinical applications.

Author information

1
Hacettepe Universitesi Tip Fakultesi.
2
King Faisal Specialist Hospital and Research Centre.
3
Taichung Veterans General Hospital.
4
National Cancer Institute, México DF.
5
Eli Lilly and Company.
6
Seoul National University School of Medicine.
7
Eli Lilly (Suisse) S.A.
8
Eli Lilly y Compañía de México.
9
Phramongkutklao Army Hospital.

Abstract

Context:

Monoclonal antibodies are being investigated for chronic pain to overcome the shortcomings of current treatment options.

Objective:

To provide a practical overview of monoclonal antibodies in clinical development for use in chronic pain conditions, with a focus on mechanisms of action and relevance to specific classes.

Methods:

Qualitative review using a systematic strategy to search for randomized controlled trials, systematic and nonsystematic (narrative) reviews, observational studies, nonclinical studies, and case reports for inclusion. Studies were identified via relevant search terms using an electronic search of MEDLINE via PubMed (1990 to June 2017) in addition to hand-searching reference lists of retrieved systematic and nonsystematic reviews.

Results:

Monoclonal antibodies targeting nerve growth factor, calcitonin gene-related peptide pathways, various ion channels, tumor necrosis factor-α, and epidermal growth factor receptor are in different stages of development. Mechanisms of action are dependent on specific signaling pathways, which commonly involve those related to peripheral neurogenic inflammation. In clinical studies, there has been a mixed response to different monoclonal antibodies in several chronic pain conditions, including migraine, neuropathic pain conditions (e.g., diabetic peripheral neuropathy), osteoarthritis, chronic back pain, ankylosing spondylitis, and cancer. Adverse events observed to date have generally been mild, although further studies are needed to ensure safety of monoclonal antibodies in early stages of development, especially where there is an overlap with non-pain-related pathways. High acquisition cost remains another treatment limitation.

Conclusion:

Monoclonal antibodies for chronic pain have the potential to overcome the limitations of current treatment options, but strategies to ensure their appropriate use need to be determined.

PMID:
29056066
PMCID:
PMC5680940
DOI:
10.1177/1744806917740233
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for Atypon Icon for PubMed Central
Loading ...
Support Center